Brazil's Cristalia gets OK to manufacture biosimilars; Merck KGaA to market anti-aging API

Brazil's Cristalia has received approval from regulator ANVISA for its facility in São Paulo to manufacture active pharmaceutical ingredients for biologics that it will use to make biosimilars of Roche's ($RHHBY) Herceptin and other drugs. Report (sub. req.)

Another Indian drugmaker has received a warning letter from the FDA. Letter

Jiangsu Nhwa Pharmaceutical says it will invest ¥400 million ($64.63 million) to build an ingredient plant in Xuzhou City. Report

Indian drugmaker GVK Biosciences says it intends to invest about 100 crore ($16.6 million) to build an active pharmaceutical ingredient plant. Report

Catalent says it has increased its investment in Redwood Bioscience, which has a platform for making homogeneous antibody-drug conjugates. Report

And Finally... Germany's Merck KGaA has struck an agreement to market an antiaging active pharmaceutical ingredient from California-based Laboratory Skin Care. Report